Literature DB >> 18487355

Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells.

Kathryn Chmura1, Xiyuan Bai, Mari Nakamura, Pitchaimani Kandasamy, Mischa McGibney, Koji Kuronuma, Hiroki Mitsuzawa, Dennis R Voelker, Edward D Chan.   

Abstract

Mycoplasma pneumoniae is an extracellular pathogen, residing on mucosal surfaces of the respiratory and genital tracts. The lack of cell walls in mycoplasmas facilitates the direct contact of the bacterial membrane with the host cell. The cell membrane of mycoplasma is the major inducer of the host pathogenic response. Airway diseases caused by M. pneumoniae include bronchiolitis, bronchitis, and rarely bronchiectasis. In such disorders, neutrophil infiltration of the airways predominates. More recently, M. pneumoniae has been implicated in the pathogenesis of asthma. Epithelial cells play an important role in recruiting inflammatory cells into the airways. Since M. pneumoniae infection of human epithelial cells induces expression of IL-8-a potent activator of neutrophils-we investigated the signaling and transcriptional mechanisms by which mycoplasma membrane induces expression of this chemokine. In BEAS-2B human bronchial epithelial cells, mycoplasma membrane fraction (MMF) increased IL-8 mRNA and protein production. Activation of the transcriptional elements activating protein-1, nuclear factor-interleukin-6, and particularly NF-kappaB are essential for optimal IL-8 production by MMF. The mitogen-activated protein kinases individually played a modest role in MMF-induced IL-8 production. Toll-like receptor-2 did not play a significant role in MMF-induction of IL-8. Antibiotics with microbicidal activity against M. pneumoniae are also known to have anti-inflammatory effects. Whereas clarithromycin, azithromycin, and moxifloxacin individually were able to inhibit TNF-alpha-induction of IL-8, each failed to inhibit MMF-induction of IL-8.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487355      PMCID: PMC2494795          DOI: 10.1152/ajplung.90204.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  74 in total

Review 1.  Antibiotics in asthma.

Authors:  David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

Review 2.  Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis?

Authors:  Sebastian L Johnston; Richard J Martin
Journal:  Am J Respir Crit Care Med       Date:  2005-06-16       Impact factor: 21.405

Review 3.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

4.  Effect of Mycoplasma pneumoniae lysate on interleukin-8 gene expression in human respiratory epithelial cells.

Authors:  Myung Hyun Sohn; Kyung Eun Lee; Sung Yon Choi; Byoung Chul Kwon; Myung Woong Chang; Kyu-Earn Kim
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

5.  [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis].

Authors:  S Kudoh; T Uetake; K Hagiwara; M Hirayama; L H Hus; H Kimura; Y Sugiyama
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1987-06

6.  Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors.

Authors:  Tohru Kikuchi; Koichi Hagiwara; Yoshihiro Honda; Kazunori Gomi; Takao Kobayashi; Hiroshi Takahashi; Yutaka Tokue; Akira Watanabe; Toshihiro Nukiwa
Journal:  J Antimicrob Chemother       Date:  2002-05       Impact factor: 5.790

7.  Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: a potential mechanism of its anti-inflammatory action.

Authors:  H Takizawa; M Desaki; T Ohtoshi; T Kikutani; H Okazaki; M Sato; N Akiyama; S Shoji; K Hiramatsu; K Ito
Journal:  Biochem Biophys Res Commun       Date:  1995-05-25       Impact factor: 3.575

Review 8.  Immunomodulatory activity and effectiveness of macrolides in chronic airway disease.

Authors:  Bruce K Rubin; Markus O Henke
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

9.  Isolation of Mycoplasma pneumoniae from asthmatic patients.

Authors:  J C Gil; R L Cedillo; B G Mayagoitia; M D Paz
Journal:  Ann Allergy       Date:  1993-01

10.  Low-dose, long-term macrolide therapy in asthma: An overview.

Authors:  Umur Hatipoglu; Israel Rubinstein
Journal:  Clin Mol Allergy       Date:  2004-03-16
View more
  17 in total

1.  Modulation of IL-8 boosted by Mycoplasma pneumoniae lysate in human airway epithelial cells.

Authors:  Kyung Eun Lee; Kyung Won Kim; Jung Yeon Hong; Kyu Earn Kim; Myung Hyun Sohn
Journal:  J Clin Immunol       Date:  2013-06-19       Impact factor: 8.317

2.  Surfactant protein A is defective in abrogating inflammation in asthma.

Authors:  Ying Wang; Dennis R Voelker; Njira L Lugogo; Guirong Wang; Joanna Floros; Jennifer L Ingram; Hong Wei Chu; Tony D Church; Pitchaimani Kandasamy; Daniel Fertel; Jo Rae Wright; Monica Kraft
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-22       Impact factor: 5.464

3.  SHP-1 as a critical regulator of Mycoplasma pneumoniae-induced inflammation in human asthmatic airway epithelial cells.

Authors:  Ying Wang; Zhou Zhu; Tony D Church; Njira L Lugogo; Loretta G Que; Dave Francisco; Jennifer L Ingram; Molly Huggins; Denise M Beaver; Jo Rae Wright; Monica Kraft
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

4.  Pulmonary surfactant phosphatidylglycerol inhibits Mycoplasma pneumoniae-stimulated eicosanoid production from human and mouse macrophages.

Authors:  Pitchaimani Kandasamy; Simona Zarini; Edward D Chan; Christina C Leslie; Robert C Murphy; Dennis R Voelker
Journal:  J Biol Chem       Date:  2011-01-04       Impact factor: 5.157

5.  Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes.

Authors:  Marinka Kartalija; Alida R Ovrutsky; Courtney L Bryan; Gregory B Pott; Giamila Fantuzzi; Jacob Thomas; Matthew J Strand; Xiyuan Bai; Preveen Ramamoorthy; Micol S Rothman; Vijaya Nagabhushanam; Michael McDermott; Adrah R Levin; Ashley Frazer-Abel; Patricia C Giclas; Judith Korner; Michael D Iseman; Leland Shapiro; Edward D Chan
Journal:  Am J Respir Crit Care Med       Date:  2012-11-09       Impact factor: 21.405

6.  Genetic variation in SP-A2 leads to differential binding to Mycoplasma pneumoniae membranes and regulation of host responses.

Authors:  Julie G Ledford; Dennis R Voelker; Kenneth J Addison; Ying Wang; Vinayak S Nikam; Simone Degan; Pitachaimani Kandasamy; Sasipa Tanyaratsrisakul; Bernard M Fischer; Monica Kraft; John W Hollingsworth
Journal:  J Immunol       Date:  2015-05-08       Impact factor: 5.422

7.  Mycoplasma pneumoniae extract induces an IL-17-associated inflammatory reaction in murine lung: implication for mycoplasmal pneumonia.

Authors:  Daisuke Kurai; Kazuhide Nakagaki; Hiroo Wada; Takeshi Saraya; Shigeru Kamiya; Yasunori Fujioka; Koh Nakata; Hajime Takizawa; Hajime Goto
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

8.  Mycobacterium abscessus glycopeptidolipid prevents respiratory epithelial TLR2 signaling as measured by HβD2 gene expression and IL-8 release.

Authors:  Lisa B Davidson; Rachid Nessar; Prakasha Kempaiah; Douglas J Perkins; Thomas F Byrd
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

9.  Qingfei Xiaoyan Wan, a traditional Chinese medicine formula, ameliorates Pseudomonas aeruginosa-induced acute lung inflammation by regulation of PI3K/AKT and Ras/MAPK pathways.

Authors:  Yuanyuan Hou; Yan Nie; Binfeng Cheng; Jin Tao; Xiaoyao Ma; Min Jiang; Jie Gao; Gang Bai
Journal:  Acta Pharm Sin B       Date:  2016-03-22       Impact factor: 11.413

10.  Role of the Mycoplasma pneumoniae/Interleukin-8/Neutrophil Axis in the Pathogenesis of Pneumonia.

Authors:  Zhengrong Chen; Xuejun Shao; Xunwu Dou; Xinxing Zhang; Yuqing Wang; Canhong Zhu; Chuangli Hao; Mingyue Fan; Wei Ji; Yongdong Yan
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.